SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 7,393 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 7,393 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.17, for a total transaction of $38,221.81. Following the transaction, the insider directly owned 614,887 shares of the company’s stock, valued at $3,178,965.79. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.21, for a total transaction of $3,167.68.
• On Tuesday, April 14th, Zhenyu Xu sold 600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.97, for a total transaction of $2,982.00.
• On Monday, April 13th, Zhenyu Xu sold 4,414 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total transaction of $21,010.64.
• On Friday, April 10th, Zhenyu Xu sold 3,706 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total transaction of $17,344.08.
• On Thursday, April 9th, Zhenyu Xu sold 1,936 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,176.64.
• On Wednesday, April 8th, Zhenyu Xu sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,552.00.

SOPHiA GENETICS Stock Performance

SOPH stock opened at $5.44 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. SOPHiA GENETICS SA has a 1 year low of $2.92 and a 1 year high of $6.30. The company has a market cap of $456.36 million, a P/E ratio of -10.46 and a beta of 0.96. The stock’s fifty day moving average price is $5.13 and its 200-day moving average price is $4.97.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The insider sales were mostly routine, pre-planned transactions tied to equity-award vesting and tax withholding, which suggests they may not signal a fundamental change in the business or management’s outlook.
• Neutral Sentiment: Multiple executives and directors, including Chairman Jurgi Camblong, CEO Ross Muken, CFO George Cardoza, and others, reported sales in the same period, increasing investor focus on insider activity.
• Negative Sentiment: Even if planned, the cluster of insider share sales can create pressure on sentiment because it may be interpreted as reduced confidence or excess supply in the stock near term.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently made changes to their positions in SOPH. First Dallas Securities Inc. bought a new position in shares of SOPHiA GENETICS in the first quarter worth about $50,000. Squarepoint Ops LLC purchased a new stake in shares of SOPHiA GENETICS during the third quarter worth about $49,000. Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS during the 4th quarter valued at approximately $49,000. Quadrature Capital Ltd bought a new stake in SOPHiA GENETICS during the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter worth approximately $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SOPH. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, SOPHiA GENETICS currently has a consensus rating of “Hold” and a consensus target price of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.